12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
ProteoTech Inc., is a private drug development Company that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting misfolded proteins and amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloid disease (including AL, TTR and AA amyloidosis).
With over 275 issued patents in its intellectual property estate, ProteoTech will soon enter proof-of-concept human clinical trials for its small molecule drug, Systebryl™, for the treatment of AL (immunoglobulin light chain) amyloidosis.
The Company is in late stage pre-clinical development with Synuclere™ for the treatment of Parkinson's disease, and is also in late stage pre-clinical development for a novel small peptide called PeptiClere™ for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of tau protein aggregation seen in tauopathies such as Alzheimer's and progressive supranuclear palsy (PSP.) This latter project is funded by a $2.3M Phase II SBIR (Small Business Innovative research) award from the National Institute on Aging. Lastly, ProteoTech has identified lead compounds that target islet amyloid fibrils present in 90% of patients with Type 2 diabetes.